A Phase 3 interventional study of MT-1186 and Placebo in ALS, sponsored by Shionogi. Terminated at 37 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Shionogi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS), based on the time from the randomization date in Study MT-1186-A02 to at least a 12-point decrease in Revised ALS Functional Rating Score (ALSFRS-R) or death, whichever happens first, over the course of the study or until oral edaravone is commercially available in that country
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral edaravone administered once daily for up to 48 weeks or until the drug is commercially available in that country.
Drug: MT-1186
Oral edaravone administered for 10 days followed by 18-day placebo (regimen denoted as on/off) for up to 48 weeks or until the drug is commercially available in that country.
Drug: MT-1186 · Drug: Placebo
Oral edaravone
Also known as: Oral edaravone
Oral
Also known as: Oral
Time From the Randomization Date in Study MT-1186-A02 to at Least a 12-point Decrease in ALSFRS-R or Death, Whichever Happens First.
The ASLFRS-R is Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised. The ALSFRS-R measures 12 aspects of physical function, ranging from one's ability to swallow and use utensils to climbing stairs and breathing. Each function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0.
Time frame: Up to 96 weeks
The Combined Assessment of Function and Survival (CAFS) Score at All Visits From Baseline in Study MT-1186-A02 to the End of Study MT-1186-A04
CAFS analysis ranks clinical outcomes on the basis of survival time and change in the ALS Functional Rating Scale-Revised (ALSFRS-R) score. A subject's score will be calculated by comparing each subject to every other subject within each treatment group in the study, resulting in a score of +1 if the outcome was better than the subject being compared, -1 if worse, and 0 if the same. The subject's score will then be calculated by summing up their comparison to all of the other subjects within each treatment group in the study as CAFS score. Patients' summary scores are ranked; a higher score indicates a better performance. The score range is from 1 to N, where N is the total sample size. Since CAFS were calculated using the imputed ALSFRS-R scores with multiple imputation method, and the maximum varies for each simulation, 383 is the maximum possible value of full range for measure of dispersion.
Time frame: Baseline, Week 72 and Week 96
Change in the Amyotrophic Lateral Sclerosis Assessment Questionnaire 40 Score at All Visits From Baseline in Study MT-1186-A02 to the End of Study MT-1186-A04
The ALSAQ-40 is a questionnaire that consists of 40 questions/items with 5 discrete scales: physical mobility, activities of daily living and independence, eating and drinking, communication, emotional reactions, ranging from 0 (best health as assessed by the scale) to 100 (worse health as assessed by the measure).
Time frame: Baseline, Week 72 and Week 96
Change in ALSFRS-R Score at All Visits From Baseline in Study MT-1186-A02 to the End of Study MT-1186-A04
The ALSFRS-R is rating scale (ratings 0 = can't do, to 4 = normal ability) used to determine participants' assessment of their capability and independence in 12 functional activities.
Time frame: Baseline, Week 72, Week 84 and Week 96
Time From the Randomization Date in Study MT-1186-A02 to Death, Tracheostomy, or Permanent Assisted Mechanical Ventilation (≥23 Hours/Day)
Time frame: Up to 96 weeks
Time From the Randomization Date in Study MT-1186-A02 to Death or Permanent Assisted Mechanical Ventilation (>23 Hours/Day)
Time frame: Up to 96 weeks
Time From the Randomization Date in Study MT-1186-A02 to Death
Time frame: Up to 96 weeks
| Milestone | Edaravone 105 mg (Once Daily) | Edaravone 105 mg (on/Off) |
|---|---|---|
| Started | 104 | 98 |
| Completed | 24 | 24 |
| Not completed | 80 | 74 |
| Withdrew: Adverse event | 21 | 16 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 7 | 9 |
| Withdrew: Study terminated by sponsor | 49 | 47 |
| Withdrew: Other | 2 | 1 |
The ASLFRS-R is Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised. The ALSFRS-R measures 12 aspects of physical function, ranging from one's ability to swallow and use utensils to climbing stairs and breathing. Each function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0.
| Month | Edaravone 105 mg (Once Daily) | Edaravone 105 mg (on/Off) |
|---|---|---|
| Time From the Randomization Date in Study MT-1186-A02 to at Least a 12-point Decrease in ALSFRS-R or Death, Whichever Happens First. | 13.9 (13.4 to 16.59) | 15.05 (13.8 to 16.62) |
CAFS analysis ranks clinical outcomes on the basis of survival time and change in the ALS Functional Rating Scale-Revised (ALSFRS-R) score. A subject's score will be calculated by comparing each subject to every other subject within each treatment group in the study, resulting in a score of +1 if the outcome was better than the subject being compared, -1 if worse, and 0 if the same. The subject's score will then be calculated by summing up their comparison to all of the other subjects within each treatment group in the study as CAFS score. Patients' summary scores are ranked; a higher score indicates a better performance. The score range is from 1 to N, where N is the total sample size. Since CAFS were calculated using the imputed ALSFRS-R scores with multiple imputation method, and the maximum varies for each simulation, 383 is the maximum possible value of full range for measure of dispersion.
| units on a scale | Edaravone 105 mg (Once Daily) | Edaravone 105 mg (on/Off) |
|---|---|---|
| Week 72 | 193.6 (4 to 383) | 189.1 (1 to 383) |
| Week 96 | 200.8 (4 to 383) | 181.6 (1 to 383) |
The ALSAQ-40 is a questionnaire that consists of 40 questions/items with 5 discrete scales: physical mobility, activities of daily living and independence, eating and drinking, communication, emotional reactions, ranging from 0 (best health as assessed by the scale) to 100 (worse health as assessed by the measure).
| Point | Edaravone 105 mg (Once Daily) | Edaravone 105 mg (on/Off) |
|---|---|---|
| Week 72 | 45.71 ± 3.14 | 45.46 ± 3.11 |
| Week 96 | 54.83 ± 4.05 | 57.91 ± 4.13 |
The ALSFRS-R is rating scale (ratings 0 = can't do, to 4 = normal ability) used to determine participants' assessment of their capability and independence in 12 functional activities.
| Point | Edaravone 105 mg (Once Daily) | Edaravone 105 mg (on/Off) |
|---|---|---|
| Week 72 | -15.02 ± 0.95 | -15.90 ± 0.95 |
| Week 84 | -16.79 ± 1.11 | -18.27 ± 1.10 |
| Week 96 | -18.21 ± 1.31 | -20.95 ± 1.32 |
| Month | Edaravone 105 mg (Once Daily) | Edaravone 105 mg (on/Off) |
|---|---|---|
| Time From the Randomization Date in Study MT-1186-A02 to Death, Tracheostomy, or Permanent Assisted Mechanical Ventilation (≥23 Hours/Day) | NA (19.36 to 21.02) | NA (19.43 to 21.13) |
| Month | Edaravone 105 mg (Once Daily) | Edaravone 105 mg (on/Off) |
|---|---|---|
| Time From the Randomization Date in Study MT-1186-A02 to Death or Permanent Assisted Mechanical Ventilation (>23 Hours/Day) | NA (NA to NA) | NA (NA to NA) |
| Month | Edaravone 105 mg (Once Daily) | Edaravone 105 mg (on/Off) |
|---|---|---|
| Time From the Randomization Date in Study MT-1186-A02 to Death | NA (NA to NA) | NA (NA to NA) |
Collected over Up to 50 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Edaravone 105 mg (Once Daily) | 15/104 (14.4%) | 33/104 (31.7%) | 24/104 (23.1%) |
| Edaravone 105 mg (on/Off) | 12/98 (12.2%) | 27/98 (27.6%) | 25/98 (25.5%) |
| Event | Edaravone 105 mg (Once Daily) | Edaravone 105 mg (on/Off) |
|---|---|---|
| DysphagiaGastrointestinal disorders | 14/104 | 5/98 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 10/104 | 10/98 |
| Amyotrophic lateral sclerosisNervous system disorders | 4/104 | 1/98 |
| FallInjury, poisoning and procedural complications | 0/104 | 2/98 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 2/104 | 2/98 |
| COVID-19Infections and infestations | 2/104 | 1/98 |
| PneumoniaInfections and infestations | 2/104 | 1/98 |
| Cardiac arrestCardiac disorders | 0/104 | 1/98 |
| Catheter site infectionInfections and infestations | 0/104 | 1/98 |
| Extradural haematomaInjury, poisoning and procedural complications | 0/104 | 1/98 |
| Event | Edaravone 105 mg (Once Daily) | Edaravone 105 mg (on/Off) |
|---|---|---|
| FallInjury, poisoning and procedural complications | 8/104 | 13/98 |
| ConstipationGeneral disorders | 7/104 | 6/98 |
| COVID-19Infections and infestations | 6/104 | 1/98 |
| DiarrhoeaGeneral disorders | 4/104 | 5/98 |
| InsomniaPsychiatric disorders | 5/104 | 5/98 |
The data collected before the first study drug dose administration date in Study MT-1186-A02 will be used as the baseline for statistical analysis in Study MT-1186-A04.
| Age, Customized(Participants) | Edaravone 105 mg (Once Daily) | Edaravone 105 mg (on/Off) | Total |
|---|---|---|---|
| Adults (18-64 years) | 134 | 122 | 256 |
| From 65-84 years | 58 | 70 | 128 |
| Sex: Female, Male(Participants) | Edaravone 105 mg (Once Daily) | Edaravone 105 mg (on/Off) | Total |
|---|---|---|---|
| Female | 69 | 70 | 139 |
| Male | 123 | 122 | 245 |
| Race/Ethnicity, Customized(Participants) | Edaravone 105 mg (Once Daily) | Edaravone 105 mg (on/Off) | Total |
|---|---|---|---|
| White | 115 | 109 | 224 |
| Black or African American | 3 | 2 | 5 |
| Asian - Japanese | 63 | 64 | 127 |
| Asian - Not Japanese | 8 | 13 | 21 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| Native Hawaiian or Pacific Islander | 0 | 1 | 1 |
| Not Reported | 0 | 1 | 1 |
| Other | 3 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jan 2022 to primary completion in Sep 2023, 20 months.
Results were first posted in Mar 2025, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.